MALASSA Project Launched: NovoArc Develops Lipid Nanoparticle Platform for a New Antibody Therapy Against Lassa Fever

The MALASSA project has officially kicked off. The project partners gathered in Amsterdam for the kick-off meeting to plan their joint work for the years ahead. We are delighted to be part of this international consortium.

What is MALASSA about?

The project aims to develop a new antibody therapy against Lassa fever. Lassa fever is an acute viral infectious disease and a hemorrhagic fever that occurs mainly in parts of West Africa. At the same time, MALASSA aims to help Europe be better prepared for pathogens like this one.

NovoArc’s contribution

NovoArc uses its unique lipids to produce tiny lipid nanoparticles. Building on this, we aim to develop a platform that enables antibodies to be produced faster, more flexibly and at larger scale, potentially saving both time and costs in manufacturing.

Within our team, Jana Kubackova is driving this work.

The consortium

We look forward to working with strong partners: Amsterdam UMC, MAbSilico, InSilicoTrials, PENTA Foundation, Polymun Scientific Immunbiologische Forschung GmbH, CEA, ERINHA, Inserm BSL4, AEFUTHA and Vaccinopolis.

News

Eurostars project NO-PNP launched: a new approach to neuropathic pain

Together with Akasi Pharma and IVRS AB, NovoArc is developing a long-acting, non-opioid treatment for neuropathic pain. NovoArc is contributing its liposomal TEL platform to the project.

Read more

Gold for NovoArc at the Born Global Champion Awards

The award honors companies that successfully enter international markets at an early stage, demonstrate strong export performance, and show the potential to create lasting global impact.

Read more

Recognized Among Austria’s Top 100 Startups

We’re incredibly proud to share that our company has been selected for TREND Magazine’s 2025 ranking of Austria’s Top 100 Startups.

Read more

More Than Teammates

Sometimes the most important work happens away from our desks.

Read more

A Visit from District Mayor Zankl

We were delighted to welcome District Mayor Zankl to our facility.

Read more

Nanoparticle Formulation Symposium 2025

We were pleased to contribute to the Nanoparticle Formulation Symposium in London as an invited speaker, sharing insights into current and emerging approaches in nanoparticle development.

Read more